When SGLT2 inhibitors were used as monotherapy or in addition to other anti-hyperglycemic therapies in type 2 diabetic patients, their fasting plasma glucose and glycated hemoglobin (HbA1c) were significantly reduced [44,45]. Here, SLC5A2 is linked to type 2 diabetes mellitus.